psychopharmacology
long-acting injectable antipsychotic drugs were developed with the intention of improving overall longterm management and treatment of schizophrenia additionally LAI anipsychotic drugs provide patients with schizophrenia an alternative treatment choice to oral antipsychotic drugs which can have a burdensome daily dosing regimen currently five LAI antipsychotic drug treatments are approved for use in the united states: long-acting formulations of fluphenazine decanoate (Prolixin) and haloperidol decanoate (Haldol decanoate) (catagorized as "typical" or first-generation antipsychotic drugs [FGAs]) and long-acting formulations of risperidone (Risperdal Consta) pariperidone palmitate (Invega Sustenna), and Olanzapine pamoate (Zyprexa Relprevv) (classified as "atypical" or second-generation antipsychotic drugs [SGAs]) the table lists approval dates indications and dosage/adminisration for these medications character istics associated with the newer atypical antipsychotic drugs include efficacy against positive symptoms, lower propensity to cause extrapyramidal side effects, tardive dyskinesia, and lower prolactin increases compared with order FGAs
the appropriate selection of a particular medication for a select patient is critical for health care professionals in the successful treatment of their patients although a detailed profiling of the clinical use of each LAI antipsychotic drug is beyond the scope of this article, a recent systematic review attemped to analyze factors related to prescriber choices and use of LAIs in daily clinical practise data in the literature could not be statistically analyzed to identify an ideal LAI patient; however, the need to ensure treatment delivery